Skip to main content
SpringerLink
Log in

Alemtuzumab/immune globulin

Grave's disease, idiopathic multicentric Castleman disease and lack of efficacy: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Rolfes L, et al. A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS. Neurology: Neuroimmunology and NeuroInflammation 7: No. 1, Jan 2020. Available from: URL: http://doi.org/10.1212/NXI.0000000000000638

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alemtuzumab/immune globulin. Reactions Weekly 1846, 18 (2021). https://doi.org/10.1007/s40278-021-92266-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-92266-9

Search

Navigation